Clinical trial
Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating…
NCT00438841 · Fred Hutchinson Cancer Center, Other · Unknown status
Key facts
| NCT number | NCT00438841 |
|---|---|
| Title | Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma |
| Official title | A Phase II Trial With VELCADE® (PS-341), Cytoxan (Cyclophosphamide), Dexamethasone and Thalomid® (VEL-CTD) in Previously Untreated Multiple Myeloma Patients |
| Lead sponsor | Fred Hutchinson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Drug |
| Interventions | bortezomib, cyclophosphamide, dexamethasone, thalidomide |
| Enrollment | 43 |
| Start date | Aug 1, 2006 |
| Primary completion | Dec 1, 2008 |
| First posted | Feb 22, 2007 |
| Last update posted | Mar 13, 2009 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: